Radium-223 dichloride

DRUG8 trials

Sponsors

Massachusetts General Hospital, University Hospital Freiburg, Ajjai Alva, MD, Hoffmann-La Roche, Icahn School of Medicine at Mount Sinai

Conditions

Bone MetastasesBony Metastases From Castrate Refractory Prostate CancerCastrate-Resistant Prostate CancerCastration-resistant Prostate CancerCastration-resistant Prostate Cancer Metastatic to BoneProstate CancerProstate Cancer MetastaticProstate Carcinoma

Phase 1

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

CompletedNCT02814669

Hoffmann-La RocheCastrate-Resistant Prostate Cancer

Start: 2016-09-23End: 2019-07-31Updated: 2019-09-24

Phase 2

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

CompletedNCT02346526

Massachusetts General HospitalCastration-resistant Prostate Cancer, Castration-resistant Prostate Cancer Metastatic to Bone, Prostate Cancer

Start: 2015-04-30End: 2020-12-31Updated: 2022-09-29

Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)

University Hospital FreiburgProstate Carcinoma

Start: 2014-12-31End: 2017-12-31Target: 274Updated: 2016-04-27

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

TerminatedNCT02582749

Ajjai Alva, MDBone Metastases, Prostate Cancer, Prostate Neoplasms

Start: 2016-04-30End: 2017-09-14Updated: 2022-07-11

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

CompletedNCT02903160

Icahn School of Medicine at Mount SinaiProstate Cancer

Start: 2017-01-13End: 2021-11-15Updated: 2024-02-07

Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy

CompletedNCT03062254

Sir Mortimer B. Davis - Jewish General HospitalProstate Cancer

Start: 2018-03-22End: 2021-07-15Updated: 2021-09-21

Unknown Phase

Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223

CompletedNCT03223597

The Netherlands Cancer InstituteBone Metastases, Prostate Cancer Metastatic

Start: 2015-01-17End: 2018-03-01Updated: 2022-04-15

The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.

CompletedNCT03368989

The University of Texas Health Science Center, HoustonBony Metastases From Castrate Refractory Prostate Cancer

Start: 2014-02-11End: 2017-02-07Updated: 2019-06-11

Related Papers

Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC.

Journal of Clinical Oncology2024-01-29

AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)

Frontiers in Medicine2022-11-1840 citations

Prostate cancer intensive, non-cross reactive therapy (PRINT) for CRPC: Interim analysis of efficacy endpoints.

Journal of Clinical Oncology2021-05-20

Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.

Journal of Clinical Oncology2020-05-2014 citations

PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of efficacy.

Journal of Clinical Oncology2020-05-20

PRINT: Prostate cancer intensive, non-cross reactive therapy for CRP—Early observations of efficacy.

Journal of Clinical Oncology2020-02-191 citations

Clinical outcomes of a Dutch prospective observational registry of metastatic castration resistant prostate cancer (mCRPC) patients treated with radium-223 (Ra-223).

Journal of Clinical Oncology2019-03-011 citations

PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of feasibility and efficacy.

Journal of Clinical Oncology2019-03-01

Abstract CT031: A phase Ib trial to study the safety and tolerability of atezolizumab with radium-223 dichloride in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Cancer Research2017-07-01